Recent advances in thymidine kinase 2 (TK2) inhibitors and new perspectives for potential applications

Current Pharmaceutical Design

Volumn 18, Issue 20, 2012, Pages 2981-2994

  Priego, Eva María ^a   Karlsson, Anna ^b   Gago, Federico ^c   Camarasa, María José ^a   Balzarini, Jan ^d   Pérez Pérez, María Jesús ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ALCALÁ   (Spain)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Enzymatic inhibitors; Mitochondrial depletion syndrome (MDS); Mitochondrial thymidine kinase 2 (TK2); Nucleoside metabolism; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; MITOCHONDRIAL DNA; PYRIMIDINE NUCLEOSIDE DERIVATIVE; PYRIMIDINE NUCLEOTIDE; THYMIDINE DERIVATIVE; THYMIDINE KINASE 1; THYMIDINE KINASE 2 INHIBITOR; THYMIDINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

CARCINOGENESIS; CATALYSIS; CHROMOSOME 16Q; DEATH; ENZYME SUBSTRATE COMPLEX; GENE; GENE MUTATION; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL DNA DEPLETION SYNDROME; MITOCHONDRIAL TOXICITY; MOLECULAR DOCKING; MOLECULAR MODEL; MYOPATHY; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TK2 GENE;

EID: 84861743662     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800672787     Document Type: Review

References (57)

1. Arner ESJ, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995; 67: 155-86.
2. Eriksson S, Munch-Petersen B, Johansson K, Eklund H. Structure and function of cellular deoxyribonucleoside kinases. Cell Mol Life Sci 2002; 59: 1327-46.
3. Van Rompay AR, Johansson M, Karlsson A. Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol Ther 2003; 100: 119-39.
4. Deville-Bonne D, El Amri C, Meyer P, et al. Human and viral nucleoside/nucleotide kinases involved in antiviral drug activation: Structural and catalytic properties. Antiviral Research 2010; 86: 101-20.
5. Munch-Petersen B. Enzymatic Regulation of Cytosolic Thymidine Kinase 1 and Mitochondrial Thymidine Kinase 2: A Mini Review. Nucleos Nucleot Nucl 2010; 29: 363-9.
6. Bradshaw HD, Deininger PL. Human Thymidine Kinase Gene-Molecular-Cloning and Nucleotide-Sequence of a Cdna Expressible in Mammalian-Cells. Mol Cell Biol 1984; 4: 2316-20.
7. Flemington E, Bradshaw HD, Trainadorge V, Slagel V, Deininger PL. Sequence, Structure and Promoter Characterization of the Human Thymidine Kinase Gene. Gene 1987; 52: 267-77.
8. Hallek M, Wanders L, Strohmeyer S, Emmerich B. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkińs lymphoma and a broad range of potential clinical applications. Annals of Hematology 1992; 65: 1-5.
9. Romain S, Christensen IJ, Chinot O, et al. Prognostic value of cytosolic thymidine kinase activity as a marker or proliferation in breast cancer. Int J Cancer 1995; 61: 7-12.
10. Chen Z, Zhou H, Li S, et al. Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumors. Anticancer Res 2008; 28: 3897-908.
11. Kim EY, Vrang L, Oberg B, Merigan TC. Anti-HIV type 1 activity of 3 '-fluoro-3 '-deoxythymidine for several different multidrugresistant mutants. Aids Res Hum Retrov 2001; 17: 401-7.
12. Balzarini J, Baba M, Pauwels R, Herdewijn P, De Clercq E. Antiretrovirus activity of 3́-fluoro-substituted and 3́-azido-substituted pyrimidine 2́,3́-dideoxynucleoside analogs. Biochem Pharmacol 1988; 37: 2847-56.
13. Wettin K, Johansson M, Zheng XY, Zhu CY, Karlsson A. Cloning of mouse mitochondrial thymidine kinase 2 cDNA. FEBS Lett 1999; 460: 103-6.
14. Wang L, Munch-Petersen B, Sjoberg AH, et al. Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Lett 1999; 443: 170-4.
15. Susan-Resiga D, Bentley AT, Lynx MD, LaClair DD, McKee EE. Zidovudine inhibits thymidine phosphorylation in the isolated perfused rat heart. Antimicrob Agents Chemother 2007; 51: 1142-9.
16. Lynx MD, McKee EE. 3 '-azido-3 '-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol 2006; 72: 239-43.
17. Welin M, Kosinska U, Mikkelsen NE, et al. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci USA 2004; 101: 17970-5.
18. Rampazzo C, Fabris S, Franzolin E, et al. Mitochondrial thymidine kinase and the enzymatic network regulating thymidine triphosphate pools in cultured human cells. J Biol Chem 2007; 282: 34758-69.
19. Wang L. Deoxynucleoside Salvage Enzymes and Tissue Specific Mitochondrial DNA Depletion. Nucleos Nucleot Nucl 2010; 29: 370-81.
20. Rampazzo C, Ferraro P, Pontarin G, et al. Mitochondrial deoxyribonucleotides, pool sizes, synthesis, and regulation. J Biol Chem 2004; 279: 17019-26.
21. Zhou X, Solaroli N, Bjerke M, et al. Progressive loss of mitochondrial DNA in thymidine kinase 2-deficient mice. Hum Mol Genet 2008; 17: 2329-35.
22. Hirano M, Marti R, Ferreiro-Barros C, et al. Defects of intergenomic communication: autosomal disorders that cause multiple deletions and depletion of mitochondrial DNA. Semin Cell Dev Biol 2001; 12: 417-27.
23. Oskoui M, Davidzon G, Pascual J, et al. Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene. Arch Neurol 2006; 63: 1122-6.
24. Mancuso M, Salviati L, Sacconi S, et al. Mitochondrial DNA depletion-Mutations in thymidine kinase gene with myopathy and SMA. Neurology 2002; 59: 1197-202.
25. Gotz A, Isohanni P, Pihko H, et al. Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndrome. Brain 2008; 131: 2841-50.
26. Suomalainen A, Isohanni P. Mitochondrial DNA depletion syndromes-Many genes, common mechanisms. Neuromuscular Disord 2010; 20: 429-37.
27. Saada A. Deoxyribonucleotides and disorders of mitochondrial DNA integrity. DNA Cell Biol 2004; 23: 797-806.
28. Pérez-Pérez MJ, Hernández AI, Priego EM, et al. Mitochondrial thymidine kinase inhibitors. Curr Top Med Chem 2005; 5: 1205-19.
29. Pérez-Pérez MJ, Priego EM, Hernandez AI, et al. Structure, physiological role, and specific inhibitors of human thymidine kinase 2 (TK2): Present and future. Med Res Rev 2008; 28: 797-820.
30. Kierdaszuk B, Krawiec K, Kazimierczuk Z, et al. Substrate/inhibitor properties of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) towards the sugar moiety of nucleosides, including O '-alkyl analogues. Nucleos Nucleot 1999; 18: 1883-903.
31. Balzarini J, Zhu CY, De Clercq E, et al. Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2. Biochem J 2000; 351: 167-71.
32. Balzarini J, Degrève B, Zhu CY, et al. 2 '-O-acyl/alkyl-substituted arabinosyl nucleosides as inhibitors of human mitochondrial thymidine kinase. Biochem Pharmacol 2001; 61: 727-32.
33. Manfredini S, Baraldi PG, Durini E, et al. Design, synthesis and enzymatic activity of highly selective human mitochondrial thymidine kinase inhibitors. Bioorg Med Chem Lett 2001; 11: 1329-32.
34. Ciliberti N, Manfredini S, Angusti A, et al. Novel selective human mitochondrial kinase inhibitors: Design, synthesis and enzymatic activity. Bioorg Med Chem 2007; 15: 3065-81.
35. Hernández AI, Balzarini J, Karlsson A, Camarasa MJ, Pérez-Pérez MJ. Acyclic nucleoside analogues as novel inhibitors of human mitochondrial thymidine kinase. J Med Chem 2002; 45: 4254-63.
36. Balzarini J, Hernández AI, Roche P, et al. Non-nucleoside inhibitors of mitochondrial thymidine kinase (TK-2) differentially inhibit the closely related herpes simplex virus type 1 TK and Drosophila melanogaster multifunctional deoxynucleoside kinase. Mol Pharmacol 2003; 63: 263-70.
37. Hernández AI, Balzarini J, Rodríguez-Barrios F, et al. Improving the selectivity of acyclic nucleoside analogues as inhibitors of human mitochondrial thymidine kinase: Replacement of a triphenylmethoxy moiety with substituted amines and carboxamides. Bioorg Med Chem Lett 2003; 13: 3027-30.
38. Hernández AI, Familiar O, Negri A, et al. N-1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem 2006; 49: 7766-73.
39. Priego EM, Balzarini J, Karlsson A, Camarasa MJ, Pérez-Pérez MJ. Synthesis and evaluation of thymine-derived carboxamides against mitochondrial thymidine kinase (TK-2) and related enzymes. Bioorg Med Chem 2004; 12: 5079-90.
40. Balzarini J, Van Daele I, Negri A, et al. Human Mitochondrial Thymidine Kinase Is Selectively Inhibited by 3 '-Thiourea Derivatives of beta-Thymidine: Identification of Residues Crucial for Both Inhibition and Catalytic Activity. Mol Pharmacol 2009; 75: 1127-36.
41. Van Daele I, Munier-Lehmann H, Froeyen M, Balzarini J, Van Calenbergh S. Rational design of 5'-thiourea-substituted alphathymidine analogues as thymidine monophosphate kinase inhibitors capable of inhibiting mycobacterial growth. J Med Chem 2007; 50: 5281-92.
42. Van Poecke S, Negri A, Gago F, et al. 3 '-[4-Aryl-(1,2,3-triazol-1-yl)]-3 '-deoxythymidine Analogues as Potent and Selective Inhibitors of Human Mitochondrial Thymidine Kinase. J Med Chem 2010; 53: 2902-12.
43. Van Poecke S, Negri A, Janssens J, et al. Synthesis, modeling and evaluation of 3 '-(1-aryl-1H-tetrazol-5-ylamino)-substituted 3 '-deoxythymidine derivatives as potent and selective human mitochondrial thymidine kinase inhibitors. Org Biomol Chem 2011; 9: 892-901.
44. Franzolin E, Rampazzo C, Pérez-Pérez MJ, et al. Bromovinyldeoxyuridine: A selective substrate for mitochondrial thymidine kinase in cell extracts. Biochem Biophys Res Commun 2006; 344: 30-6.
45. Frangini M, Rampazzo C, Franzolin E, et al. Unchanged thymidine triphosphate pools and thymidine metabolism in two lines of thymidine kinase 2-mutated fibroblasts. FEBS J 2009; 276: 1104-13.
46. McGuffin LJ, Smith RT, Bryson K, Sorensen SAJ, D. T. High throughput profile-profile based fold recognition for the entire Human proteome. BMC Bioinformatics 2006; 7: 288.
47. Kelley LA, Sternberg MJE. Protein structure prediction on the Web: a case study using the Phyre server. Nature Protocols 2009; 4: 363-71.
48. Holm L, Rosenstrom P. Dali server: conservation mapping in 3D. Nucleic Acids Res 2010; 38: W545-W9.
49. Egeblad-Welin L, Sonntag Y, Eklund H, Munch-Petersen B. Functional studies of active-site mutants from Drosophila melanogaster deosyribonucleoside kinase. Investigations of the putative catalytic glutamate-arginine pair and of residues responsible for substrate specificity. FEBS J 2007; 274: 1542-51.
50. Hakansson P, Hofer A, Thelander L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem 2006; 281: 7834-41.
51. Pontarin G, Ferraro P, Rampazzo C, et al. Deoxyribonucleotide Metabolism in Cycling and Resting Human Fibroblasts with a Missense Mutation in p53R2, a Subunit of Ribonucleotide Reductase. J Biol Chem 2011; 286: 11132-40.
52. Apostolova N, Blas-García A, Espluques JV. Mitochondrial toxicity in HAART: an overview of in vitro evidence. Curr Pharm Design 2011; 17: 2130-44.
53. Payne BAI, Wilson IJ, Hateley CA, et al. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet 2011; 43: 806-U121.
54. Lu J, Sharma LK, Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Research 2009; 19: 802-15.
55. Bartesaghi S, Betts-Henderson J, Cain K, et al. Loss of thymidine kinase 2 alters neuronal bioenergetics and leads to neurodegeneration. Hum Mol Genet 2010; 19: 1669-77.
56. Zhou X, Johansson M, Solaroli N, et al. Hematopoiesis in the thymidine kinase 2 deficient mouse model of mitochondrial DNA depletion syndrome. J Inherit Metab Dis 2010; 33: 231-6.
57. Samudio I, Fiegl M, Andreeff M. Mitochondrial Uncoupling and the Warburg Effect: Molecular Basis for the Reprogramming of Cancer Cell Metabolism. Cancer Res 2009; 69: 2163-6.